72
Background: Assay-vendor independent quality control (QC) samples for neurochemical dementia diagnostics (NDD) biomarkers are so far commercially unavailable. This requires that NDD laboratories prepare their own QC samples, for example by pooling leftover cerebrospinal fluid (CSF) samples. Objective: To prepare and test alternative matrices for QC samples that could facilitate intra-and inter-laboratory QC of the NDD biomarkers. ier to obtain different biomarkers concentrations (for 91 example "normal" and "pathologic" levels) in syn-92 thetic matrices than in pooled CSF leftovers. In our 93 previous study [11] , we addressed the feasibility of Table 1 . Short-and long-term stability was evaluated ; b) Stabilized A␤ ; c) Non-stabilized A␤ (Innotest); d) Stabilized A␤ (Innotest); e) Non-stabilized A␤ (MSD); f) Stabilized A␤ (MSD). Table 1 Normalized concentrations of the biomarkers tested for short-term stability in human pooled CSF samples (A0 and A+) 
294

RESULTS
295
Short-term stability
296
If not stated otherwise, the results of the stability 297 studies are presented as normalized concentrations.
298
The normalization was performed by division of the 299 concentration measured in a given sample by the con-300 centration measured in the reference sample, i.e., the 301 sample placed into -80 • C freezer immediately after 302 its preparation.
303
The results of the STS testing of the human In brackets, coefficients of variation and average daily decrease (%/d, percent per day) of the concentrations are presented. The averages and the CV's were calculated from the results of the days 1-7, 10, and 14 (i. e. omitting the results of the reference samples of the "Day 0", defined as 100%). NaN 3 , a sample containing NaN 3 as an antibacterial stabilizer; NS, non significant. In brackets, coefficients of variation and average daily decrease (%/d, percent per day) of the concentrations are presented. The averages and the CVs were calculated from the results of the days 1-7, 10, and 14 (i.e., omitting the results of the reference samples of the "Day 0", defined as 100%). NaN 3 , a sample containing NaN 3 as an antibacterial stabilizer; NS, non significant. reported by the participants of the inter-center study 410 are presented in Fig. 4 and (Fig. 4b) . A␤ Similar results were obtained for A␤ (Fig. 4d) ; biomarkers [12] .
455
At the beginning of this study (Summer 2012) 
475
In our study, three matrices were tested: (A) human which should meet at least minimal quality criteria.
483
For example, such samples should be collected in 
517
Following the recommendations by Linsinger et al.
518
[15], we tested stability of the biomarkers in two set-519 tings: Short-term, which included three temperature 520 conditions, and long-term, which was performed on 521 the samples kept at -80 • C (usual long-term storage 522 condition).
523
To test short-term stability, we applied the 524 isochronous method [16, 17] , which means that the are sufficiently stable at this temperature [18, 19] and other laboratories [23] .
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